IBRUTINIB INCREASES THE SYSTEMIC EXPOSURE OF RITUXIMAB: PHARMACOKINETIC RESULTS FROM THE HELIOS TRIAL
Sign Up to like & getrecommendations! Published in 2017 at "Hematological Oncology"
DOI: 10.1002/hon.2438_95
Abstract: decreased lymphoma‐specific mortality, adjusted HR 0.09 (0.01, 0.64). Further dose‐response analyses are planned. Conclusions: In this very large population‐based unselected lymphoma population, statins were not associated with worse outcomes and thus appear safe to use… read more here.
Keywords: pharmacokinetic results; exposure rituximab; ibrutinib increases; increases systemic ... See more keywords
Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial
Sign Up to like & getrecommendations! Published in 2019 at "Pharmaceutical Research"
DOI: 10.1007/s11095-019-2605-8
Abstract: IntroductionIn the HELIOS trial, bendamustine/rituximab (BR) plus ibrutinib (BR-I) improved disease outcomes versus BR plus placebo in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. Here, we describe the pharmacokinetic (PK) observations, along with modeling to… read more here.
Keywords: rituximab; trial; exposure rituximab; systemic exposure ... See more keywords
Septic Episodes in a Premature Infant After In Utero Exposure to Rituximab
Sign Up to like & getrecommendations! Published in 2017 at "Pediatrics"
DOI: 10.1542/peds.2016-2819
Abstract: This case report suggests a clinically significant immunocompromised state subsequent to in utero exposure to rituximab in a preterm infant with 2 episodes of sepsis. Rituximab is an increasingly used immunotherapeutic agent for women of… read more here.
Keywords: premature infant; exposure; septic episodes; exposure rituximab ... See more keywords